Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 2
1948 1
1950 3
1951 2
1952 2
1953 2
1954 2
1955 1
1957 1
1958 1
1959 3
1960 3
1961 2
1962 1
1963 1
1964 2
1965 1
1966 1
1968 1
1969 2
1970 2
1971 4
1972 1
1973 1
1975 1
1978 2
1979 2
1980 2
1982 1
1983 1
1986 2
1987 4
1988 3
1989 1
1990 3
1991 10
1992 4
1993 6
1994 3
1995 12
1996 2
1997 2
1998 7
1999 7
2000 11
2001 12
2002 15
2003 4
2004 10
2005 15
2006 16
2007 13
2008 17
2009 19
2010 23
2011 30
2012 31
2013 29
2014 33
2015 25
2016 21
2017 26
2018 21
2019 20
2020 13
Text availability
Article attribute
Article type
Publication date

Search Results

474 results
Results by year
Filters applied: . Clear all
Page 1
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Kappos L, et al. Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Lancet. 2018. PMID: 29576505 Clinical Trial.
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.
Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group. Uccelli A, et al. Among authors: Fernandez O. Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z. Trials. 2019. PMID: 31072380 Free PMC article. Clinical Trial.
Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.
Hausenloy DJ, Kharbanda RK, Møller UK, Ramlall M, Aarøe J, Butler R, Bulluck H, Clayton T, Dana A, Dodd M, Engstrom T, Evans R, Lassen JF, Christensen EF, Garcia-Ruiz JM, Gorog DA, Hjort J, Houghton RF, Ibanez B, Knight R, Lippert FK, Lønborg JT, Maeng M, Milasinovic D, More R, Nicholas JM, Jensen LO, Perkins A, Radovanovic N, Rakhit RD, Ravkilde J, Ryding AD, Schmidt MR, Riddervold IS, Sørensen HT, Stankovic G, Varma M, Webb I, Terkelsen CJ, Greenwood JP, Yellon DM, Bøtker HE; CONDI-2/ERIC-PPCI Investigators. Hausenloy DJ, et al. Lancet. 2019 Oct 19;394(10207):1415-1424. doi: 10.1016/S0140-6736(19)32039-2. Epub 2019 Sep 6. Lancet. 2019. PMID: 31500849 Free PMC article. Clinical Trial.
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Kapoor R, et al. Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. Lancet Neurol. 2018. PMID: 29545067 Clinical Trial.
Cancelled operations: a 7-day cohort study of planned adult inpatient surgery in 245 UK National Health Service hospitals.
Wong DJN, Harris SK, Moonesinghe SR; SNAP-2: EPICCS collaborators; Health Services Research Centre, National Institute of Academic Anaesthesia; Study Steering Group; Net Solving Limited; Trainee Research Networks; Abertawe Bro Morgannwg University Health Board; Aintree University Hospitals NHS Foundation Trust; Airedale NHS Foundation Trust; Aneurin Bevan Health Board; Ashford & St Peters NHS Foundation Trust; Barking, Havering and Redbridge University Hospitals NHS Trust; Barnsley Hospital NHS Foundation Trust; Barts Health NHS Trust; Basildon and Thurrock University Hospitals NHS Foundation Trust; Bedford Hospital NHS Trust; Belfast Health and Social Care Trust; Betsi Cadwaladr University Health Board; Birmingham Women's NHS Foundation Trust; Blackpool Teaching Hospitals NHS Foundation Trust; Bolton Hospital NHS Foundation Trust; Bradford Teaching Hospitals NHS Foundation Trust; Brighton and Sussex University Hospitals NHS Trust; Buckinghamshire Healthcare NHS Trust; Burton Hospitals NHS Foundation Trust; Calderdale and Huddersfield NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cardiff and Vale University Health Board; Central Manchester University Hospitals NHS Foundation Trust; Chelsea and Westminster Hospital NHS Foundation Trust; Chesterfield Royal Hospital NHS Foundation Trust; Christie Hospital NHS Foundation Trust; City Hospitals Sunderland NHS Foundation Trust; Colchester Hospital University NHS Foundation Trust; Countess of Chester NHS Foundation Trust; County Durham and Darlington NHS Foundation Trust; Croydon Health Services NHS Trust; Cwm Taf University Health Board; Dartford and Gravesham NHS Trust; Derby Hospitals NHS Foundation Trust; Doncaster and Bassetlaw Hospitals NHS Foundation Trust; Dorset County Hospital NHS Foundation Trust; Dudley Group NHS Foundation Trust; East and North Hertfordshire NHS Trust; East Kent Hospitals University NHS Foundation Trust; East Lancashire Hospitals NHS Trust; East Sussex Healthcare NHS Trust; Epsom and St Helier University Hospitals NHS Trust; Frimley Health NHS Foundation Trust; Gateshead Health NHS Foundation Trust; Gloucestershire Hospitals NHS Foundation Trust; Great Western Hospitals NHS Foundation Trust; Guy's and St Thomas' NHS Foundation Trust; Hampshire Hospitals NHS Foundation Trust; Harrogate and District NHS Foundation Trust; Heart Of England NHS Foundation Trust; Hillingdon Hospitals NHS Foundation Trust; Homerton University Hospital NHS Foundation Trust; Hull and East Yorkshire Hospitals NHS Trust; Hywel Dda Health Board; Imperial College Healthcare NHS Trust; Ipswich Hospital NHS Trust; Isle of Wight NHS Trust; James Paget University Hospitals NHS Foundation Trust; Kettering General Hospital NHS Foundation Trust; King's College Hospital NHS Foundation Trust; Kingston Hospital NHS Foundation Trust; Lancashire Teaching Hospitals NHS Foundation Trust; Leeds Teaching Hospitals NHS Trust; Lewisham and Greenwich NHS Trust; Liverpool Women's NHS Foundation Trust; Luton and Dunstable University Hospital NHS Foundation Trust; Medway NHS Foundation Trust; Mid Cheshire Hospitals NHS Foundation Trust; Mid Essex Hospital Services NHS Trust; Mid Yorkshire Hospitals NHS Trust; Milton Keynes University Hospital NHS Foundation Trust; Newcastle upon Tyne Hospitals NHS Foundation Trust; NHS Ayrshire & Arran; NHS Dumfries & Galloway; NHS Fife; NHS Greater Glasgow & Clyde; NHS Highland; NHS Lanarkshire; NHS Lothian; NHS Scotland Special Board; NHS Shetland; NHS Tayside; Norfolk and Norwich University Hospitals NHS Foundation Trust; Northampton General Hospital NHS Trust; North Bristol NHS Trust; North Cumbria University Hospitals NHS Trust; Northern Devon Healthcare NHS Trust; Northern Health and Social Care Trust; Northern Lincolnshire and Goole Hospitals NHS Foundation Trust; North Middlesex University Hospital NHS Trust; North Tees and Hartlepool NHS Trust; Northumbria Healthcare NHS Foundation Trust; North West Anglia NHS Foundation Trust; Nottingham University Hospitals NHS Trust; Oxford University Hospitals NHS Foundation Trust; Papworth Hospital NHS Foundation Trust; Pennine Acute NHS Trust; Plymouth Hospitals NHS Trust; Poole Hospital NHS Foundation Trust; Portsmouth Hospitals NHS Trust; Princess Alexandra Hospital NHS Trust; Queen Elizabeth Hospital NHS Foundation Trust; Queen Victoria Hospital NHS Foundation Trust; Robert Jones and Agnes Hunt Orthopaedic Hospital Foundation Trust; Rotherham NHS Foundation Trust; Royal Berkshire NHS Foundation Trust; Royal Bournemouth & Christchurch Hospitals NHS Foundation Trust; Royal Cornwall Hospitals NHS Trust; Royal Devon and Exeter NHS Foundation Trust; Royal Free London NHS Foundation Trust; Royal Liverpool and Broadgreen University Hospitals NHS Trust; Royal Marsden NHS Foundation Trust; Royal National Orthopaedic Hospital NHS Trust; Royal Orthopaedic Hospital NHS Foundation Trust; Royal Surrey County Hospital NHS Foundation Trust; Royal United Hospitals Bath NHS Trust; Royal Wolverhampton Hospitals NHS Trust; Salford Royal NHS Foundation Trust; Salisbury NHS Foundation Trust; Sandwell and West Birmingham Hospitals NHS Trust; Sheffield Teaching Hospitals NHS Foundation Trust; Shrewsbury and Telford Hospital NHS Trust; South Eastern Health and Social Care Trust; Southport and Ormskirk Hospital NHS Trust; South Tees Hospitals NHS Foundation Trust; South Tyneside NHS Foundation Trust; South Warwickshire NHS Foundation Trust; St George's Healthcare NHS Trust; St Helens and Knowsley Teaching Hospitals NHS Trust; Stockport NHS Foundation Trust; Surrey and Sussex Healthcare NHS Trust; Tameside Hospital NHS Foundation Trust; Taunton and Somerset NHS Foundation Trust; Torbay and South Devon NHS Foundation Trust; United Lincolnshire Hospitals NHS Trust; University College London Hospitals NHS Foundation Trust; University Hospital of North Midlands NHS Trust; University Hospital of South Manchester NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; University Hospitals Bristol NHS Foundation Trust; University Hospitals Coventry and Warwickshire NHS Trust; University Hospitals of Leicester NHS Trust; University Hospitals of Morecambe Bay NHS Foundation Trust; University Hospital Southampton NHS Foundation Trust; Walsall Healthcare NHS Trust; Warrington & Halton Hospitals NHS Foundation Trust; Western Health and Social Care Trust; Western Sussex Hospitals NHS Foundation Trust; West Herts Hospitals NHS Trust; Weston Area Health NHS Trust; West Suffolk NHS Foundation Trust; Whittington Hospital NHS Trust; Wirral University Teaching Hospital NHS Foundation Trust; Worcestershire Acute Hospitals NHS Trust; Wrightington, Wigan and Leigh NHS Foundation Trust; Wye Valley NHS Trust; Yeovil District Hospital NHS Foundation Trust; York Teaching Hospital NHS Foundation Trust. Wong DJN, et al. Br J Anaesth. 2018 Oct;121(4):730-738. doi: 10.1016/j.bja.2018.07.002. Epub 2018 Sep 7. Br J Anaesth. 2018. PMID: 30236235 Free article. Clinical Trial.
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI; SYNERGY study investigators. Cadavid D, et al. Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5. Lancet Neurol. 2019. PMID: 31285147
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Fox RJ, et al. N Engl J Med. 2012 Sep 20;367(12):1087-97. doi: 10.1056/NEJMoa1206328. N Engl J Med. 2012. PMID: 22992072 Free article. Clinical Trial.
Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks.
Alroughani R, Altintas A, Al Jumah M, Sahraian M, Alsharoqi I, AlTahan A, Daif A, Dahdaleh M, Deleu D, Fernandez O, Grigoriadis N, Inshasi J, Karabudak R, Taha K, Totolyan N, Yamout BI, Zakaria M, Bohlega S. Alroughani R, et al. Among authors: Fernandez O. Mult Scler Int. 2016;2016:1034912. doi: 10.1155/2016/1034912. Epub 2016 Dec 18. Mult Scler Int. 2016. PMID: 28078140 Free PMC article. Review.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. Cohen JA, et al. N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089954 Free article. Clinical Trial.
474 results
Jump to page
Feedback